Oncology
-
FDA Fully Approves Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
INDIANAPOLIS, September 19 — Eli Lilly and Company announced on Sept. 18, 2026, that the U.S. Food and Drug Administration granted full…
-
How Oncotype DX Works: The 21-Gene Recurrence Score Explained
MUNICH, July 17 — A gene expression profiling test that has become a standard tool in breast cancer treatment decisions works by…
-
Review Names dCK Enzyme as Metabolic Target for Cancer Therapy
LOS ANGELES, July 17 — A new comprehensive review is pointing cancer researchers toward an old metabolic enzyme, one that could offer…
-
Harvard Cancer Researchers Retract 2019 Paper Over Duplicated Images
BOSTON, July 17 — A research paper whose corresponding author is a prominent Boston oncologist has been retracted, raising questions in the…
-
Clinical Risk Score Helps Guide Chemotherapy Choices for Younger Women After Oncotype DX Test
NEW YORK, July 17 — For patients facing a breast cancer diagnosis, the decision about chemotherapy has long been one of medicine’s…
-
Dr. Joseph Sparano, TAILORx Lead Author, and the Trial That Spared Many Women Chemotherapy
NEW YORK, July 17 — A landmark clinical trial that reshaped how oncologists treat early-stage breast cancer has its roots in the…
-
Oncotype DX Evidence: What TAILORx and NCCN Ratings Show
WASHINGTON, July 17 — The strategic calculus of breast cancer treatment has shifted decisively over the past two decades, driven by a…
-
Delphi Diagnostics Offers Endocrine Activity Index Test for Stage II-III Breast Cancer
LONDON, July 17 — The genomic test that changed how oncologists decide whether to give chemotherapy for early breast cancer now has…
-
Multi-cancer blood tests show early promise, but doctors want proof they work
ROME, July 16 — The shift is happening in plain sight. Cancer detection is moving from single-organ biopsies to a single blood…
-
Ernexa Plans Fourth-Quarter First-in-Human Trial of ERNA-101 in Ovarian Cancer
SAN FRANCISCO, July 15 — Ernexa Therapeutics, a biotechnology company operating in the U.S. healthcare sector, is preparing to advance its lead…
-
ERNA-101 Platform Targets Cancer with Differentiated Therapy
NEW YORK, July 15 — A new targeted cancer therapy platform is moving toward its first human trials, offering a potential advance…
-
Ernexa Plans IND Filing in Q3 and Ovarian Cancer Trial in Q4 2026
NEW YORK, July 15 — Ernexa Therapeutics is moving its lead candidate ERNA-101 toward a first-in-human Phase 1 study, with the trial…
-
Ernexa Therapeutics Advances ERNA-101 to First-in-Human Trial Planning
SINGAPORE, July 15 — A new cancer therapy candidate is taking its first step from the laboratory bench toward the bedside, with…
-
Akeso starts US Phase II cadonilimab trial in gastric cancer with Memorial Sloan Kettering
ISLAMABAD, July 15 — Akeso, the Chinese biopharmaceutical company, has advanced its investigational drug cadonilimab into a Phase II clinical trial in…
-
Pioneering pharmacologist honored for breast cancer breakthrough
WASHINGTON, July 15 — V. Craig Jordan, the British-American pharmacologist whose work turned tamoxifen into a cornerstone of hormone-positive breast cancer therapy,…
-
James Allison’s CTLA-4 Discovery Pioneered Cancer Checkpoint Therapy
HOUSTON, July 14 — The technical reality of cancer immunotherapy is that the body’s own T cells often have the means to…
-
Immunotherapy harnesses immune system to fight cancer tumors
NEW YORK, July 14 — When James Allison and Tasuku Honjo shared the Nobel Prize in Physiology or Medicine in 2018, they…
-
Chinese Biotech Deals With Big Pharma Surge as Drugmakers Face Patent Cliff
BEIJING, July 13 — Cross-border deals for innovative drugs originating from China have reached a record US$110 billion in the first half…
-
Jammu and Kashmir reviews draft cancer care strategy to cut patient travel
SRINAGAR, July 13 — The Chief Secretary of Jammu and Kashmir, Atal Dulloo, chaired a high-level meeting here today to formulate a…
-
NYU AI Test Edges Out Oncotype DX in Predicting Breast Cancer Recurrence
NEW YORK, July 12 — A new AI tool from New York University may offer a cheaper alternative to genomic tests for…
-
Immunotherapy Side Effects Affect More Than 60% of Patients, MD Anderson Says
WASHINGTON, July 10 — The strategic calculus of cancer treatment is shifting, and with it comes a new set of battlefield risks…
-
FDA Immunotherapy Approvals Reach 156 Since 2011, Cancer Research Institute Reports
WASHINGTON, July 10 — The first checkpoint inhibitor landed in March 2011, a drug called ipilimumab, approved for melanoma. Since then, the…
-
Nobel Laureate Dr. James Allison’s CTLA-4 discovery launched immunotherapy
HOUSTON, July 10 — The man who taught the immune system to fight cancer has spent the better part of three decades…
-
Sea Squirt Compound Shows Promise Against Melanoma Cells
NEW YORK, July 8 — 1%. That figure that matters: melanoma accounts for about 1% of all skin cancers, yet it causes…
Most read
-
First Human Data on ER-100: What the Sinclair-Linked Eye Gene Therapy Actually Showed
-
AACR Report Details Rapid Progress in Targeted Cancer Therapies and Survival
-
Study Links High Sugar Intake to 28% Higher Breast Cancer Risk in Korean Women
-
Dexcom CONNECT Study Shows CGM Lowers A1C by 1.6% in Non-Insulin Type 2 Diabetes
-
How Satri-Cel Became the World’s First Approved Solid Tumor CAR-T
-
Missed NHS England cancer‑treatment target threatens bladder‑cancer surgery waiting times
-
AstraZeneca’s Imfinzi Wins FDA Approval for Bladder Cancer Patients
-
How Kazia’s Nuclear PD-L1 Degrader Aims to Overcome Cancer Resistance
-
FDA RMAT and Fast Track Designations Set New Evidence Bar for Cell Therapies
-
How mRNA Technology Is Transforming the Future of Personalized Cancer Vaccines
-
Workers Can Boost Tax Savings by Maximizing New $3,500 Health FSA Limit for 2027
-
Fidelity’s Shift to Managed Accounts and Private Assets: What It Means for 401(k) Savers
-
How Required Minimum Distributions Work and Strategies to Lower Taxes
-
How the 2027 401(k) Limit Increase to $25,500 Changes Retirement Planning
-
BMS GPRC5D CAR-T Arlo-cel Shows Deep Responses After BCMA Failure
-
Understanding the FDA’s Accelerated Approval of Iberdomide for Multiple Myeloma
-
Rockefeller’s 2141-V11 Trial Shows Complete Remission in Two Metastatic Cancer Patients
-
Ellie Sullivan: Genetic Testing Refused for a Decade, Then Offered After Her Diagnosis
-
Personalized mRNA Cancer Vaccine Succeeds in First Phase 3 Melanoma Trial
-
Indiana University Study Ties Delayed Colorectal Cancer Treatment to Higher Metastasis Risk
-
Study: People Who Drank More Water With Meals Ate More Food, Not Less
-
Why Mornings Are Hardest With ADHD: Late Body Clocks, Poor Sleep and Dopamine
-
Immunotherapy and Genome-Based Vaccines Put the Immune System to Work Against Disease
-
Geneticist John Hardy Proposed Alzheimer’s Amyloid Hypothesis in 1992